BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-148@catalystbrief.girapphe.com
DTSTAMP:20261118T181553Z
LAST-MODIFIED:20261118T181553Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Pfizer — Ritlecitinib higher dose [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Learn About Medicine Cal
 led Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopec
 ia Areata.\nSource: https://clinicaltrials.gov/study/NCT07029711\nhttps://
 catalystbrief.girapphe.com/e/148?lang=en\nNot investment advice. Dates may
  change.
URL:https://catalystbrief.girapphe.com/e/148?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
